Beta amyloid

Overview

Beta amyloid (Aβ) is a peptide that plays a critical role in the pathogenesis of Alzheimer's disease (AD). It is derived from the amyloid precursor protein (APP) through the action of beta-secretase (BACE1) and gamma-secretase enzymes. The accumulation of Aβ in the brain leads to the formation of amyloid plaques, which are considered one of the hallmark features of Alzheimer's disease. These plaques contribute to neuroinflammation, tau protein hyperphosphorylation, and neuronal loss, ultimately resulting in cognitive decline. The understanding of Aβ's role in Alzheimer's has spurred significant research into therapeutic strategies aimed at reducing its aggregation and mitigating its neurotoxic effects.

Focus of Latest Publications

Recent investigations have expanded understanding of beta amyloid (A␤) pathology and therapeutic targeting across multiple modalities. Monoclonal antibody approaches continue to demonstrate efficacy: aducanumab showed robust A␤ burden reduction in postmortem brain tissue from treated patients, though with redistribution to cerebral microvessels and selective reduction of neuritic phospho-tau without affecting established neurofibrillary tangles. Donanemab, which targets the insoluble plaque form of A␤, significantly slows cognitive and functional decline in mild cognitive impairment and mild dementia cohorts. Complementary small-molecule strategies are being pursued, including glucagon-like peptide-1 receptor agonists (semaglutide, tirzepatide, liraglutide), which inhibit A␤42 aggregation by targeting primary nucleation with submicromolar potency. Butyrate supplementation reduces A␤42 accumulation at the blood–brain barrier endothelium through activation of insulin signaling pathways (AKT and ERK), while restoring expression of critical transporter and tight-junction proteins.

Biomarker and stratification studies reveal A␤'s complex relationship with other pathologies in early disease. Plasma phosphorylated tau-217 combined with tau-PET visual assessments delineate distinct trajectories of A␤ and tau accumulation, neurodegeneration, and cognitive decline in cognitively unimpaired, amyloid-positive older adults. Cerebral amyloid angiopathy—present in over 90% of Alzheimer's disease cases and a significant risk factor for amyloid-related imaging abnormalities during anti-amyloid treatment—is now detectable through a plasma protein signature combining CRP, IL-4, CCL11, NPY, and PDLIM5. Longitudinal analysis in community-based cohorts reveals that vitamin B12 and Folate deficiencies associate with cognitive impairment partly through effects on neurofilament light chain and glial fibrillary acidic protein, demonstrating interconnected metabolic pathways affecting A␤ biomarker status.

Novel nanoparticle and immunological platforms represent an expanding frontier in A␤ targeting. Ferritin-based nanoparticle vaccines conjugating A␤1-6 epitopes elicit high-titer antibodies recognizing neurotoxic A␤42 oligomers, clearing A␤ plaques in cortical and hippocampal regions while rescuing spatial memory deficits in transgenic mice. Multifunctional nanoplatforms—including near-infrared carbon dots, glutathione-conjugated gold nanoparticles, and covalent organic framework composites—integrate A␤ antiaggregation, metal ion chelation, and reactive oxygen species scavenging into single agents. Engineered nanobodies derived from camelids offer advantages in blood–brain barrier penetration and specific A␤ targeting without conventional antibody-associated limitations.

Emerging research increasingly emphasizes multi-target and patient-stratified approaches. Retrospective analysis of the AMARANTH trial (lanabecestat, a BACE1 inhibitor reducing A␤ production) identified patient subgroups responding to treatment through artificial intelligence-driven clustering, demonstrating slower cognitive decline in enriched populations despite no overall trial benefit. Natural compounds including chrysin, lawsone, and daurioxoisoporphine D show neuroprotective effects coupled with A␤ aggregation inhibition. A mathematical modeling framework demonstrates that multi-target combination therapies achieve superior control of A␤ oligomer accumulation compared to monotherapies, with potential for dose optimization to reduce costs while maintaining efficacy. Together, these studies reflect a shift toward precision medicine strategies that account for disease heterogeneity and complex amyloid biology rather than pan-population interventions.

Key Publications

• NEWJun Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease. (Alzheimer's research & therapy, 2026, PMID 42337598): "Here, we identified concordant and discordant profiles based on combined plasma p-tau217 status and tau-PET visual assessments in cognitively unimpaired amyloid-β (Aβ)-positive older adults and investigated whether these profiles delineate distinct longitudinal trajectories of Aβ and tau accumulation, neurodegeneration, and cognitive decline."
• NEWJun Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease. (Acta neuropathologica, 2026, PMID 42301522): "Patients treated with aducanumab displayed a robust reduction in Aβ burden."
• Jun Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026, PMID 42222928): "Immunotherapy targeting amyloid beta (Aβ) is limited by amyloid-related imaging abnormalities (ARIA), hypothesized to result from the direct binding of anti-Aβ monoclonal antibodies (mAbs) to vascular cerebral amyloid angiopathy (CAA), eliciting an immune response."
• May Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. (Purinergic signalling, 2026, PMID 42213219): "testing Lanabecestat, a BACE1 inhibitor decreasing β-amyloid production in Alzheimer's disease, for which traditional analysis reported no efficacy."
• May Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. (Lancet (London, England), 2026, PMID 42208562): "Alzheimer's disease neuropathology, characterised by amyloid β (Aβ) and phosphorylated-tau (p-tau) protein accumulation, has primarily been assessed with biomarkers in clinical samples of older adults."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42166642)
• May A plasma protein signature for cerebral amyloid angiopathy. (Acta neuropathologica, 2026, PMID 42162487): "Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid-β (Aβ) in the walls of leptomeningeal and cortical blood vessels that increases risk of intracerebral hemorrhages and progressive cognitive decline."
• May Chrysin Ameliorated Neurochemical and Behavioural Changes Mediated By Combined Exposure of Interleukin-17 A With Amyloid Beta1-42 in Mice. (Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026, PMID 42149389): "Moreover, the combination of recombinant IL-17 A with amyloid beta (Aβ1-42) has been shown to be involved in promoting neuroinflammation during AD pathology."
• May Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. (Journal of the American Chemical Society, 2026, PMID 42133988): "Herein, we investigated five FDA-approved GLP-1RAs, and show semaglutide, tirzepatide, and liraglutide inhibit Aβ42 aggregation."
• May Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. (Neurology. Clinical practice, 2026, PMID 42128444): "Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia."